Upload Records Snowball Search Search OpenAlex
About the database ScholarIQanswers from OpenAlex
Befotertinib (D-0316) versus icotinib as first-line therapy for patients with EGFR-mutated locally advanced or metastatic non-small-cell lung cancer: a multicentre, open-label, randomised phase 3 study
PaperCitations, authors & open-access status
Befotertinib (D-0316) versus icotinib as first-line therapy for patients with EGFR-mutated locally advanced or metastatic non-small-cell lung cancer: a multicentre, open-label, randomised phase 3 study is a paper indexed in ScholarIQ from OpenAlex. ScholarIQ records 72 citations, 2023 year and closed oa status.
72
Citations
2023
Year
closed
OA Status